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Abstract
Background: Arterial stiffness has been suggested as a valuable predictor of coronary artery stenosis (CAS). However,
little data are available on aortic stiffness and CAS in patients who have previously undergone percutaneous coronary
artery intervention (PCI). The aim of this study was to investigate the association of arterial stiffness to CAS in patients
with a history of PCI and those without a history of PCI.
Methods: We retrospectively studied 1093 consecutive patients who had undergone coronary angiography (CAG).
Arterial stiffness was determined by brachial-ankle pulse wave velocity (baPWV) measured prior to CAG.
Results: In patients without a history of PCI, baPWV significantly increased in patients with CAS compared to that in
patients without CAS (p < 0.001). However, among patients with a history of PCI, there was no significant difference in
baPWV. Multivariate logistic regression analysis demonstrated that baPWV was an independent risk predictor for CAS in
patients without a history of PCI, but not in those with a history of PCI (OR 1.106, 95% CI 1.039–1.177, p = 0.002). In CAS
patients without a history of PCI, increased baPWV was significantly associated with multiple cardiovascular risk factors,
multivessel involvement, and anatomical severity.
Conclusions: Prediction of CAS by baPWV is significantly attenuated in patients with a history of PCI.
Keywords: Aortic stiffness, Pulse wave velocity, Coronary artery stenosis, Percutaneous coronary artery intervention
Study highlights
1. baPWV is significantly increased in CAS patients without a
history of PCI compared to those non-CAS patients.
2. baPWV is an independent risk predictor for CAS
3. Higher baPWV is associated with multiple vessel
involvement and angiographic severe disease.
4. The relationship between baPWV and CAS was attenuated
in patients with abnormal ABI.
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Background
Despite advances in risk stratification and its treatment,
coronary artery disease remains a leading cause of mor-
bidity and mortality worldwide. Coronary atherosclerosis
and subsequent coronary plaque development are the
main pathognomonic signs of coronary artery disease.
Thus, early detection of coronary plaque and coronary
artery stenosis (CAS) is important for the management
of this disease.
Coronary angiography (CAG) continues to be consid-
ered the gold standard procedure for the diagnosis of
CAS. However, its invasiveness limits its clinical use
exclusively to subjects with a high-risk profile for CAS.
Although many non-invasive techniques may be used to
detect CAS, including the treadmill test, stress echocardi-
ography, myocardial perfusion scanning, and computed
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tomographic angiography, these too have limitations when
applied to asymptomatic subjects or subjects with a low-
risk profile.
Recently, arterial stiffness has emerged as a potential
candidate for the prediction of cardiovascular disease
[1–3]. It too is associated with other cardiovascular risk
factors, including age, hypertension and diabetes melli-
tus [4–6]. Various methods have been employed to
measure arterial stiffness. Among them, pulse wave vel-
ocity (PWV) and the augmentation index (AIx) have
been frequently used as reliable indicators of arterial
stiffness [7]. Brachial-ankle pulse wave velocity (baPWV)
can be measured non-invasively to estimate the conven-
tional carotid-femoral PWV [8]. However, the associ-
ation of baPWV or AIx with CAS is still controversial.
Some studies have reported that baPWV is a meaningful
risk predictor for CAS [9, 10]. In contrast, other studies
have reported the limited value of baPWV to predict
CAS [11]. Moreover, the discrepancy of baPWV and AIx
for CAS has been also reported [12, 13]. At present, no
data are available on baPWV and AIx in patients who
have previously undergone percutaneous coronary inter-
vention (PCI).
The purpose of the present study was to explore the
association between arterial stiffness (measured by PWV
and AIx) and CAS in patients who have already under-
gone percutaneous coronary intervention (PCI) as com-




This was a single-center, retrospective study of consecu-
tive patients who underwent both CAG and arterial stiff-
ness measurements from January 2011 through January
2013. It was approved by the ethical committee of the
institutional review board of Korea University Anam
Hospital, and the need for written informed consent was
waived due to the non-interventional and retrospective
nature of the study. After excluding the patients with
acute coronary syndrome, underlying valvular heart dis-
ease or prior surgical coronary revascularization, a total
of 1093 patients were identified and divided into 4
groups as follows: (Group 1, n = 326) absence of CAS
without prior PCI history, (Group 2, n = 457) presence
of CAS without prior PCI history, (Group 3, n = 120) ab-
sence of CAS with prior PCI history, and (Group 4, n =
190) presence of CAS with prior PCI history (Fig. 1).
Coronary artery stenosis (CAS)
CAS was angiographically defined as a >50% diameter
stenosis in at least one major coronary artery (left anter-
ior descending artery, left circumflex artery, or right
coronary artery). The extent of vessel involvement was
divided into 0-, 1-, 2-, and 3-vessel groups. The anatom-
ical severity of CAS was determined by using the modi-
fied Gensini score [14].
Non-invasive hemodynamic parameter measurement
baPWV and ankle-brachial index (ABI) were measured
non-invasively using an oscillometric sphygmomanometric
device (VP-1000 plus; Omron Colin, Kyoto, Japan). Central
systolic blood pressure (cSBP) and AIx were also measured
non-invasively by using an applanation tonometry device
(HEM9000A1; Omron Colin, Kyoto, Japan). cSBP was
estimated from the late systolic shoulder (SBP2) of the
radial pulse waveform. Because AIx is significantly in-
fluenced by heart rate, an index normalized for a heart
rate of 75 bpm (AIx@75) was used. All these measure-
ments were performed the day prior to CAG. The val-
idity and reproducibility of the measurements have
been previously described [8, 15].
Statistical analysis
Continuous variables were expressed as the mean ± SD.
Comparisons between the 2 groups were performed
using an independent Student’s t-test for continuous var-
iables and χ2 test for categorical variables. To identify
the risk predictors for CAS, selected factors from all var-
iables were tested using a multivariate logistic regression
analysis by univariate analysis (p < 0.10). An odds ratio
with a 95% confidence interval and P-value were re-
ported. Receiver operating characteristic (ROC) curves
were constructed for the diagnosis of significant coron-
ary artery stenosis. Two academic authors separately an-
alyzed the database and reconciled any discrepancies. All
tests were two-sided. A P-value of less than 0.05 was
considered statistically significant. All statistical analyses
were performed using the Statistical Package for the
Social Sciences (SPSS) software package (Version 18.0,
SPSS Inc., Chicago, IL, USA).
Fig. 1 Study design. CAG: coronary angiography, PCI: percutaneous
coronary angiography, CAS: coronary artery stenosis, cSBP: central
systolic blood pressure, baPWV: brachial-ankle pulsed wave velocity,
ABI: ankle-brachial index, AIx: augmentation index
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Results
Baseline demographic characteristics
Demographic features of study subjects are presented in
Table 1. Patients with a history of PCI (Groups 3 and 4)
were significantly older, predominantly male, and pre-
sented with a higher incidence of typical or atypical
chest pain, hypertension, diabetes, dyslipidemia, and im-
paired renal function compared to the patients without a
history of PCI (Groups 1 and 2). Patients with a history
of PCI were more frequently receiving ACE inhibitors,
angiotensin receptor blockers, beta-blockers, calcium
channel blockers, insulin and statins than patients with
no history of PCI. However, among the patients without
a history of PCI, the patients with CAS (Group 2) had
more typical chest pain compared to those without
CAS (Group 1). Among patients with a history of PCI,
patients without CAS (Group 3) were older and had a
higher incidence of diabetes than patients with CAS
(Group 4).
Non-invasive hemodynamic parameters and CAS
Non-invasive hemodynamic parameters are summarized
in Table 2. Among patients without a history of PCI,
those with CAS (Group 2) had a significantly lower
diastolic blood pressure (DBP), higher pulse pressure,
lower cSBP, higher baPWV, and lower ABI than patients
Table 1 Baseline demographic characteristics
Variables Group 1 Group 2 p-value
(1 vs 2)




Age (year) 58.9 ± 10.04 59 ± 10.89 0.896 63.88 ± 8.32 61.41 ± 10.04 0.020 <0.001
Male (%) 182 (55.83%) 259 (56.67%) 0.814 84 (70%) 148 (77.89%) 0.119 <0.001
Symptoms
Asymptomatic 70 (20.5%) 66 (14.4%) 0.001 75 (62.5%) 96 (50.5%) 0.078 <0.001
Atypical chest pain 127 (39.0%) 149 (32.6%) 15 (12.5%) 24 (12.6%)
Typical chest pain 129 (39.6%) 242 (53.0%) 30 (25.0%) 70 (36.8%)
BMI (kg/m2) 24.9 ± 3.09 24.71 ± 2.97 0.391 24.68 ± 2.8 24.99 ± 3.04 0.356 0.683
Smoking (%) 97 (29.75%) 138 (30.2%) 0.894 38 (31.67%) 51 (26.84%) 0.360 0.671
Hypertension (%) 191 (58.4%) 266 (58.3%) 1.000 108 (90.0%) 180 (94.7%) 0.172 <0.001
Diabetes mellitus (%) 61 (18.71%) 82 (17.94%) 0.784 46 (38.33%) 50 (26.32%) 0.026 <0.001
Dyslipidemia (%) 95 (29.14%) 149 (32.6%) 0.302 102 (85%) 164 (86.32%) 0.746 <0.001
CKD (%) 69 (21.23%) 110 (24.07%) 0.352 42 (35%) 53 (27.89%) 0.186 0.008
Uric acid (mg/dL) 5.14 ± 1.48 5.25 ± 1.44 0.337 5.3 ± 1.63 5.42 ± 1.34 0.493 0.085
Hba1c (% of THb) 6.19 ± 1.04 6.29 ± 1.41 0.539 6.48 ± 1.08 6.02 ± 0.82 0.005 0.644
TC (mg/dL) 147.8 ± 89.48 157.3 ± 103.2 0.168 123.7 ± 63.19 133.7 ± 80.2 0.226 <0.001
LDL-C (mg/dL) 96.5 ± 26.88 96.13 ± 27.24 0.853 72.64 ± 20.31 73.07 ± 21.8 0.860 <0.001
HDL-C (mg/dL) 51.31 ± 13.57 49.95 ± 12.83 0.157 48.1 ± 11.29 46.89 ± 11.36 0.361 <0.001
Triglyceride (mg/dL) 137.5 ± 89.21 152.3 ± 105.9 0.036 119.6 ± 67.36 129.9 ± 82.59 0.231 <0.001
Creatinine (mg/dL) 0.96 ± 0.46 0.95 ± 0.23 0.672 1.06 ± 0.65 1.02 ± 0.2 0.479 0.003
hsCRP (mg/L) 2.74 ± 8.99 2.15 ± 5.68 0.324 2.01 ± 4.32 1.82 ± 4 0.701 0.162
#, risk factorsa 2.23 ± 1.39 2.29 ± 1.35 0.579 3.67 ± 1.25 3.48 ± 0.97 0.152 <0.001
Index Medications
ACE inhibitors (%) 12 (3.68%) 15 (3.28%) 0.763 35 (29.17%) 55 (28.95%) 0.967 <0.001
ARBs (%) 87 (26.69%) 101 (22.1%) 0.139 52 (43.33%) 68 (35.79%) 0.184 <0.001
Beta-blockers (%) 35 (10.74%) 62 (13.57%) 0.236 47 (39.17%) 88 (46.32%) 0.216 <0.001
CCB (%) 84 (25.77%) 135 (29.54%) 0.246 47 (39.17%) 83 (43.68%) 0.432 <0.001
Diuretics (%) 27 (8.28%) 28 (6.13%) 0.245 12 (10%) 15 (7.89%) 0.522 0.340
Insulin (%) 2 (0.61%) 2 (0.44%) 1.000 4 (3.33%) 5 (2.63%) 0.739 0.003
Statins (%) 77 (23.62%) 116 (25.38%) 0.573 102 (85%) 163 (85.79%) 0.848 <0.001
BMI body mass index, CKD chronic kidney disease, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ACE
angiotensin-converting enzyme, ARB angiotensin receptor blocker, CCB calcium channel blocker
aRisk factors included old age (≥65 years), male gender, smoking, hypertension, diabetes mellitus, and dyslipidemia. Data are presented as means ± SDs for
continuous variables and numbers (%) for categorical variables
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without CAS (Group 1). However, among patients with a
history of PCI, those with CAS (Group 4) had a signifi-
cantly higher pulse pressure than those without CAS
(Group 3).
To explore the potential risk predictors for CAS, we
performed univariate and multivariate logistic regression
analyses (Table 3). In the total population, the use of
RAS inhibitors and statins, DBP, cSBP, baPWV, ABI, and
AIx@75 were independent risk predictors for CAS. In
patients without a history of PCI, hypertension, the use
of CCB, DBP, cSBP, baPWV, ABI, and AIx@75 were
independent risk predictors for CAS. In patients with a
history of PCI, diabetes mellitus, DBP, cSBP, and AIx@75
were independent risk predictors for CAS.
Thus, baPWV significantly increased in CAS patients
without a history of PCI as an independent risk pre-
dictor for CAS.
baPWV and coronary artery disease risk factors
Next, we compared baPWVs dependent to the pres-
ence or absence of conventional cardiovascular risk
factors, which included age (≥65 years), gender, smok-
ing, hypertension, type 2 diabetes mellitus, and dyslip-
idemia (Fig. 2a). Among patients without a history of
PCI, baPWV increased significantly in smokers than in
non-smokers (p = 0.03). baPWV was also higher in
male patients than female patients, although this dif-
ference was not significant (p = 0.10). Among patients
with a history of PCI, baPWV decreased significantly
in diabetic patients than in non-diabetic patients (p =
0.03). Interestingly, among patients without a history
of PCI, baPWV increased significantly in patients with
CAS or multiple conventional coronary artery disease
risk factors (Fig. 2b). However, among patients without
a history of PCI, the number of conventional coronary
artery risk factors or CAS did not affect baPWV. These
data suggest that increased baPWV in CAS patients
without a history of PCI could be associated with an
overall increase in cardiovascular risk.
baPWV and the severity of CAS
Although baPWV did not significantly differ with the num-
bers of stenotic major coronary arteries in patients with a
history of PCI, baPWV increased significantly in cases of
2-vessel or greater involvement in patients without a his-
tory of PCI (Fig. 3, left panel). Patients were divided into 4
groups according to their modified Gensini score: Q1 =
zero, Q2 = 0.5 to 9.5, Q3 = 10 to 29.5 and Q4 = 30 and
over. In both patients with and without a history of PCI,
baPWVs in Q2, Q3, and Q4 were significantly higher than
those in Q1 (Fig. 3, right panel). This suggests that baPWV
increased significantly even in patients with mild coronary
artery stenosis (the modified Gensini score > 0.5), regard-
less of a history of PCI. Interestingly, in patients without a
history of PCI, baPWV in Q4 was significantly higher than
that in Q3 (p = 0.039). When taken in conjunction with the
extent of vessel involvement, these data suggest that
baPWV showed a trend towards a positive correlation
with anatomical severity and multivessel involvement in
patients without a history of PCI.
Effect of ABI on baPWV and CAS
ABI is a well-known indicator for peripheral artery dis-
ease [16]. The reference value for ABI is known to be
1.0–1.29. A value of less than 0.9 suggests significant
stenosis of the lower limb artery. A value greater than
Table 2 Comparisons of SBP, DBP, pulse pressure, cSBP, baPWV, ABI, Aix, and AIx@75
Variables Group 1 Group 2 p-value
(1 vs 2)




SBP (mmHg) 130.3 ± 17.72 130.7 ± 17.12 0.762 129.2 ± 15.15 131.9 ± 17.25 0.196 0.804
DBP (mmHg) 77.56 ± 10.77 74.12 ± 11.76 <0.001 78.34 ± 9.98 76.26 ± 11.8 0.141 0.067
Pulse pressure (mmHg) 52.75 ± 13.95 56.6 ± 13.37 <0.001 50.84 ± 12.74 55.63 ± 13.45 0.004 0.222
cSBP (mmHg) 135.2 ± 20.99 134.2 ± 19.33 0.529 134.5 ± 18.23 136.3 ± 19.71 0.467 0.488
baPWV (right, cm/sec) 1518.6 ± 292.1 1607.4 ± 342.6 <0.001 1521.4 ± 241.3 1572.4 ± 339.3 0.124 0.409
baPWV (left, cm/sec) 1517.4 ± 292.0 1592.4 ± 335.5 0.001 1533.0 ± 250.9 1559.6 ± 319.0 0.416 0.574
baPWV (average, cm/sec) 1517.7 ± 289.1 1599.8 ± 326.7 <0.001 1526.8 ± 241.6 1566.0 ± 323.8 0.226 0.476
ABI (right) 1.13 ± 0.09 1.12 ± 0.1 0.142 1.12 ± 0.08 1.12 ± 0.11 0.795 0.343
ABI (left) 1.13 ± 0.08 1.1 ± 0.12 <0.001 1.12 ± 0.08 1.11 ± 0.11 0.571 0.604
ABI (average) 1.13 ± 0.07 1.11 ± 0.1 0.007 1.12 ± 0.08 1.12 ± 0.11 0.700 0.820
AIx (%) 81.73 ± 14.64 80.96 ± 14.36 0.492 82.19 ± 16.25 81.37 ± 13.8 0.661 0.700
AIx@75 (%) 79.8 ± 13.26 78.11 ± 12.5 0.090 80.58 ± 14.02 79.23 ± 11.81 0.402 0.314
Data are presented as means ± SDs
SBP systolic blood pressure, DBP diastolic blood pressure, cSBP central systolic blood pressure, baPWV brachial-ankle pulsed wave velocity, ABI ankle-brachial index,
AIx augmentation index, AIx@75 AIx normalized for a heart rate of 75 bpm
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Table 3 Univariate and multivariate analyses for coronary artery stenosis (CAS)
Variable Univariate analysis Multivariate analysis
Exp(B) OR (95% CI) p-value Exp(B) OR (95% CI) p-value
Total population
Age 0.995 0.983–1.007 0.403
Male 1.148 0.896–1.470 0.276
BMI 0.995 0.956–1.036 0.808
Smoking 0.951 0.730–1.237 0.706
Hypertension 0.840 0.659–1.071 0.159
Diabetes mellitus 0.812 0.608–1.085 0.159
Dyslipidemia 1.184 0.930–1.509 0.171
CKD 1.013 0.767–1.339 0.926
RAS inhibitor 0.843 0.658–1.080 0.177 0.680 0.497–0.931 0.016
Beta-blocker 1.340 0.991–1.811 0.057
CCB 1.222 0.941–1.586 0.132
Statin 1.131 0.885–1.445 0.325 1.477 1.084–2.014 0.014
SBP 1.004 0.996–1.011 0.356
DBP 0.977 0.965–0.988 <0.001 0.951 0.935–0.967 <0.001
PP 1.023 1.013–1.034 <0.001
cSBP 0.999 0.993–1.006 0.876 1.021 1.008–1.033 0.001
baPWV 1.001 1.000–1.001 <0.001 1.075 1.021–1.133 0.006
ABI 0.202 0.053–0.774 0.020 0.094 0.019–0.468 0.004
AIx@75 0.990 0.980–1.001 0.064 0.976 0.963–0.989 <0.001
Patients without prior PCI history
Age 1.001 0.987–1.014 0.895
Male 1.035 0.777–1.378 0.814
BMI 0.980 0.935–1.027 0.390
Smoking 1.021 0.749–1.393 0.894
Hypertension 0.796 0.599–1.059 0.118 0.667 0.462–0.964 0.031
Diabetes mellitus 0.950 0.658–1.371 0.783
Dyslipidemia 1.176 0.864–1.602 0.303
CKD 1.176 0.836–1.655 0.352
RAS inhibitor 0.806 0.586–1.108 0.183
Beta-blocker 1.305 0.839–2.029 0.237
CCB 1.208 0.878–1.662 0.247 1.552 1.032–2.333 0.035
Statin 1.100 0.790–1.532 0.573
SBP 1.001 0.993–1.010 0.762
DBP 0.974 0.961–0.987 <0.001 0.952 0.933–0.971 <0.001
PP 1.022 1.010–1.034 <0.001
cSBP 0.998 0.990–1.005 0.528 1.016 1.001–1.030 0.034
baPWV 1.001 1.000–1.001 <0.001 1.106 1.039–1.177 0.002
ABI 0.123 0.024–0.621 0.011 0.039 0.006–0.273 0.001
AIx@75 0.990 0.978–1.002 0.091 0.979 0.963–0.995 0.010
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1.3 suggests non-compressible calcified vessels. An ab-
normal value of ABI could indicate atherosclerosis or an
arteriosclerotic change to the blood vessels [17]. In the
present study, we further analyzed baPWV and CAS de-
pendence on ABI. Interestingly, in patients without a
history of PCI, baPWV significantly increased only in
CAS patients with normal ABI (Fig. 4). Abnormal ABI
attenuated the baPWV increase in CAS patients. This
suggests that baPWV could not predict CAS in patients
with vascular atherosclerosis or arteriosclerotic changes
as determined by ABI.
Diagnostic potential of baPWV for CAS
Based on the ROC curves, we analyzed the accuracy
of baPWV in predicting CAS. ROC curves in patients
with and without a history of PCI are presented in
Fig. 5. The area under the curve (AUC) of baPWV in
patients with a history of PCI was determined to be
non-significant (AUC = 0.520, p = 0.548), while that of
baPWV in patients without a history of PCI was sig-
nificantly higher than the reference value (AUC =
0.576, p < 0.001). Using a cut-off value of 1488.5 cm/s
for baPWV, a sensitivity of 59.6% and specificity of
50.2% were obtained. A cut-off value of 1561 cm/s
for baPWV produced a 50.8% sensitivity and a 62.5%
specificity value.
Discussion
Coronary atherosclerosis and arteriosclerosis are the path-
ognomonic processes leading to coronary vascular injury.
Arterial stiffness reflects the functional and structural vas-
cular changes that occur during atherosclerosis and ar-
teriosclerosis [18]. Previous studies have demonstrated
that arterial stiffness is significantly associated with an in-
creased risk of coronary artery disease [2, 19, 20] and car-
diovascular events [21, 22]. Moreover, measurement of
arterial stiffness is often recommended to evaluate vascular
damage in daily clinical practice. Recent guidelines have
recommended carotid-femoral PWV measurement for the
evaluation of asymptomatic organ damage in hypertensive
patients [23]. Although carotid-femoral PWV has been
used as a conventional method for the measurement of ar-
terial stiffness, baPWV has been extensively studied as an
alternative method given its ease and convenience.
Numerous studies have shown that an increased baPWV
is significantly associated with the presence of CAS [9–11].
In the present study, baPWV significantly increased only in
CAS patients without a history of PCI (Table 2). In
addition, multivariate analyses showed baPWV to be an
independent predictor for CAS only in patients without
a history of PCI (Table 3). Considering that previous
studies in the literature excluded patients with a history
of PCI, the results of the present study correspond to
those previously published.
Table 3 Univariate and multivariate analyses for coronary artery stenosis (CAS) (Continued)
Patients with prior PCI history
Age 0.972 0.948–0.997 0.026
Male 1.510 0.898–2.539 0.120
BMI 1.038 0.959–1.123 0.355
Smoking 0.792 0.480–1.307 0.361
Hypertension 0.928 0.578–1.488 0.756
Diabetes mellitus 0.575 0.352–0.937 0.027 0.556 0.318–0.970 0.039
Dyslipidemia 1.113 0.581–2.132 0.747
CKD 0.718 0.440–1.174 0.187
RAS inhibitor 0.735 0.450–1.198 0.217
Beta-blocker 1.340 0.842–2.132 0.217
CCB 1.205 0.757–1.919 0.433
Statin 1.066 0.559–2.033 0.847
SBP 1.010 0.995–1.026 0.196
DBP 0.983 0.961–1.006 0.142 0.953 0.923–0.984 0.003
PP 1.029 1.008–1.049 0.005
cSBP 1.005 0.992–1.018 0.465 1.032 1.010–1.054 0.004
baPWV 1.000 1.000–1.001 0.256
ABI 0.640 0.058–7.095 0.716
AIx@75 0.992 0.972–1.011 0.401 0.971 0.947–0.996 0.024
RAS inhibitor refers to ACE inhibitors or ARBs
CKD chronic kidney disease, OR odds ratio, 95% CI 95% confidence interval
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Formerly, arterial stiffness was known to be associated
with conventional cardiovascular risk factors, including
age, hypertension, and diabetes mellitus [4–6]. The find-
ings of the present study show that, although there were
significant differences in clinical profiles (including car-
diovascular risk factors) between patients with and with-
out a history of PCI, the presence of each conventional
cardiovascular risk factor (age, gender, smoking, hyper-
tension, diabetes mellitus, and dyslipidemia) had little
effect on baPWV in both patients with and without a
history of PCI (Fig. 2a). Interestingly, baPWV increased
in CAS patients without a history of PCI while overall
cardiovascular risk increased (Fig. 2b). This association
between baPWV and overall cardiovascular risk was not
shown in patients without CAS or patients with a history
of PCI. These findings suggests that baPWV could play a
role in predicting CAS in patients at modest cardiovascular
risk, such as those with more than 2 cardiovascular risk
factors and no history of PCI.
In previous studies, the relationship between
baPWV and the severity of CAS have shown conflict-
ing results. Xiong et al. reported a strong relationship
between baPWV and CAS severity as assessed by the
SYNTAX score [24]. On the other hand, Chae et al.
reported a non-significant relationship between baPWV
and multivessel involvement of CAS [9]. Both studies
included only patients without a history of PCI. Inter-
estingly, the present study demonstrated that an
increased baPWV was related to both multivessel in-
volvement and the increased, modified Gensini score
in patients without a history of PCI. Furthermore, this
relationship was attenuated in patients with a history
of PCI.
In this study, baPWV was not increased in CAS
patients with a history of PCI. There are several
factors to consider when explaining the relationship
between baPWV and CAS and a history of PCI as
observed in the present study.
Fig. 2 baPWV and coronary artery disease risk factors. a Comparisons of baPWV according to coronary artery disease risk factors and history of PCI. b
Comparisons of baPWV according to CAS and the number of coronary artery disease risk factors. *p < 0.05 versus CAS (−). HTN: hypertension, T2DM:
type 2 diabetes mellitus
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First, the baseline demographic characteristics showed
significant differences between the patients with and
without a history of PCI (Table 1). Patients with a his-
tory of PCI were older, male-predominant and frequently
asymptomatic. These patients were also presented with
an increased incidence of hypertension, diabetes, dyslip-
idemia and renal function impairment. The medication
which was administered to these patients varied widely.
Previously published studies have reported different re-
sults regarding this relationship between baPWV and
CAS in different study populations. Seo et al. reported
that baPWV had the limited value as a predictor of CAS
in the patients with a high-risk profile [25]. Park et al.
also showed that baPWV failed to predict CAS in the
patients with suspected stable angina by means of a
standard medical history and stress test [26]. When we
analyzed the diagnostic potential of baPWV according to
the pre-test probability based on the patient symptom,
baPWV was significant for CAS only in asymptomatic
or atypical chest pain patients without prior PCI history
(Additional file 1: Table S1). It supported the previous
underlying assumption that baPWV could have potential
to predict CAS in low probability patients.
Second, atherosclerosis and arteriosclerosis in other
types of arteries could affect baPWV and act as con-
founding factors in the prediction of CAS. While both
conditions are known to elicit overall vascular changes
as opposed to localized effects, they often cause different
types of vascular diseases such as coronary artery disease
and other peripheral occlusive arterial disease. ABI is
thought to be reflective of atherosclerotic changes to the
peripheral arteries in lower limbs [27, 28] and is widely-
used to evaluate and diagnose peripheral artery disease
[29–31]. Conventionally, a low ABI (<0.9) represents sig-
nificant arterial stenosis of the lower extremities and a
high ABI (>1.2) represents abnormal arterial stiffness
and hardening. Interestingly, although there was no sig-
nificant difference in baPWV according to ABI and CAS
in patients with a history of PCI in this study (data not
shown), comparison of baPWV according to ABI in pa-
tients without a history of PCI did show that baPWV
was elevated only in CAS patients with normal ABI
(Fig. 4). This further suggests that vascular changes in
Fig. 3 baPWV and angiographical disease severity. Comparisons of baPWV according to the number of stenotic coronary arteries or the modified
Gensini score. *p < 0.05 versus patients with no stenotic coronary artery or the lowest modified Gensini score (Q1)
Fig. 4 Comparisons of baPWV according to ABI and CAS in patients
without a history of PCI
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other arteries may have significantly limited the efficacy
of baPWV in the prediction of CAS, even in patients
without a history of PCI.
Finally, the present study showed that the overall diag-
nostic potential of baPWV for CAS, even in patients with-
out a history of PCI, was somewhat limited. Although the
AUC in the ROC curve was statistically significant, a cut-
off value of 1561 cm/s produced only a 50.8% sensitivity
and a 62.5% specificity (Fig. 5). Based on previous reports,
the suggested cut-off values of baPWV for the prediction
of CAS vary greatly from 1540 cm/s to 2150 cm/s [9, 10].
Sensitivities and specificities for CAS in the literature are
65.0–76.7% and 56.7–61.0%, respectively, which are too
low to have any clinical implications. In addition, previous
studies have also shown that baPWV failed to predict the
risk of revascularization [9].
The limitations of this study must be taken into con-
sideration. First, this study was a single-center, retro-
spective, cross-sectional study, which cannot determine
causality. Second, we did not assess the treatment deci-
sions made, including revascularization for patients with
CAS. Third, although the present study successfully
showed the significance of baPWV for CAS, its diag-
nostic potential was quite poor. To investigate its clin-
ical implication, it should be kept being researched
whether baPWV could provide the additional statistical
power to the conventional patient stratification, and
finally improve the overall predictability for CAS.
Conclusions
In conclusion, baPWV could play a role in predicting
CAS and its severity only in patients without a history
of PCI. However, its diagnostic potential for CAS is
quite limited, and vascular changes in other arteries
detected by ABI significantly attenuate their correl-
ation. The clinical value of follow-up baPWV meas-
urement in patients with CAS remains to be further
investigated.
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